SUM149PT Xenograft Model Service for Breast Cancer

The SUM149PT xenograft model delivers a highly specialized, clinically relevant in vivo translational platform specifically optimized for evaluating candidate therapies and overcoming therapeutic resistance in aggressive, BRCA1-mutated inflammatory triple-negative breast cancer (TNBC). Alfa Cytology provides a comprehensive, end-to-end SUM149PT xenograft model service, integrating authenticated cell line logistics with validated engineering workflows to streamline preclinical oncology drug development.

Overview of SUM149PT Xenograft Model for Breast Cancer

The SUM149PT cell line is a premier and highly physiological human mammary carcinoma model utilized in preclinical oncology to investigate the biology of inflammatory breast cancer (IBC), the most lethal and aggressive form of locally advanced breast malignancy. Originally isolated from a primary infiltrating ductal carcinoma of a patient with locally advanced IBC, this model is molecularly classified within the basal-like subtype of TNBC, demonstrating an absolute absence of ER, PR, and HER2 expression. Crucially, SUM149PT harbors a distinct genomic hallmark featuring a heterozygous frame-shift mutation in the BRCA1 tumor suppressor gene (specifically the 2288delT mutation), coupled with a loss of the wild-type allele. This genetic configuration leads to homologous recombination deficiency (HRD) and a compromised DNA damage response, making the SUM149PT model a vital test matrix for validating novel PARP inhibitors, platinum-based chemotherapies, and targeted agents inhibiting cell cycle checkpoints or mitotic machinery.

When established in vivo as a xenograft in immunocompromised mice, SUM149PT cells develop into highly angiogenic, poorly differentiated solid tumors that preserve the classical histopathological phenotype of IBC, including rapid dermal lymphatic invasion and high metastatic potential.

Cell Line Information: SUM149PT

The SUM149PT cell line maintains a distinct epithelial morphology in vitro and reliably preserves its signature BRCA1 mutational architecture, inflammatory features, and triple-negative status upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the SUM149PT Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including microvascular density analysis and PK/PD assessments. Leveraging our expertise in BRCA1-mutated inflammatory TNBC models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of SUM149PT Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the SUM149PT xenograft model:

• Cell Culture & Quality Control: SUM149PT cells are cultivated in specialized, serum-supplemented growth media enriched with insulin and hydrocortisone under precise atmospheric conditions. Quality control involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic purity before inoculation.
• Host Selection & Acclimatization: Standardized highly immunodeficient mice (such as NOD/SCID or NCG strains) are chosen to accommodate the specific engraftment demands of inflammatory lines, followed by acclimatization to controlled facility parameters.
• Precision Inoculation: A precisely calibrated suspension of high-viability SUM149PT cells is prepared and blended with a validated, basement-membrane-matrix carrier to optimize local cell attachment and mimic the stroma. The mixture is precisely injected in vivo via the orthotopic mammary fat pad or subcutaneous routes.
• Longitudinal Growth Tracking: Following successful model establishment, tumor kinetics are recorded systematically using high-precision digital calipers under continuous animal health monitoring. Visual inspection for local inflammatory skin manifestations is also performed routinely.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimized volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. SUM149PT Xenograft Model Construction Workflow

Case Study - SUM149PT Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the SUM149PT xenograft model was successfully utilized to evaluate the synergy between a novel selective PARP inhibitor and an anti-EGFR targeted agent in a setting mimicking refractory inflammatory breast cancer. Under optimized modeling conditions and precise matrix-supported orthotopic inoculation protocols, our technical team achieved uniform tumor engraftment and low-variance growth curves across all immunodeficient cohorts, enabling an unobstructed assessment of therapeutic benefit.

Our Advantages

Choosing the right partner for your aggressive, BRCA1-mutated inflammatory triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable BRCA1 mutations and validated inflammatory breast cancer phenotypes.
• Technical Consistency: Tailored inoculation strategies using advanced matrix support to guarantee uniform tumor growth and minimize experimental variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, microvascular density analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, BRCA1-mutated inflammatory triple-negative breast cancer using the robust SUM149PT xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.